Narrative Update on Bio-Techne
Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.
What's in the News
- Saguaro Biosciences announced a new distribution agreement with Bio-Techne, leveraging Bio-Techne's global sales and marketing channels to distribute non-toxic, wash-free dyes for advanced cell-based assays. (Client Announcements)
- Bio-Techne enhanced its agreement with Oxford Nanopore Technologies, expanding development and commercialization of genetic products through 2032. This includes targeted enrichment sequencing kits for heritable genetic disorder screening. (Strategic Alliances)
- Bio-Techne introduced advancements in its spatial biology portfolio, with new capabilities for RNAscope™ ISH and Lunaphore COMET™. The goal is to integrate RNA and protein biomarker detection into clinical workflows, as showcased at the National Society of Histotechnology (NSH) Convention. (Product-Related Announcements)
- Bio-Techne was dropped from the FTSE All-World Index (USD). (Index Constituent Drops)
- The company completed a share buyback of 1,943,140 shares, representing 1.24%, for $100.05 million as of June 30, 2025. (Buyback Tranche Update)
Valuation Changes
- Fair Value Estimate has increased slightly from $66.23 to $67.08.
- Discount Rate has risen marginally from 7.29% to 7.35%.
- Revenue Growth Forecast has decreased from 6.53% to 5.88%.
- Net Profit Margin Expectation has improved from 16.97% to 17.28%.
- Future P/E Ratio Projection has edged up from 47.42x to 48.10x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.